Thromboxane A2 synthetase inhibitor failed to ameliorate the arterial narrowing during the chronic phase of cerebral vasospasm
- 29 August 1997
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 61 (14) , 1371-1377
- https://doi.org/10.1016/s0024-3205(97)00682-6
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 1995
- Levels of Catecholamine in Plasma and Cerebrospinal Fluid in Aneurysmal Subarachnoid HemorrhageNeurosurgery, 1992
- The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogsActa Neurochirurgica, 1988
- Pharmacological Studies on the TXA2 Synthetase Inhibitor (E)-3-[p(1H-lmidazol-1-Ylmethyl)Phenyl]-2-Propenoic Acid (OKY-046)The Japanese Journal of Pharmacology, 1986
- Beneficial Effect of OKY-046, a Selective Thromboxane A2 Synthetase Inhibitor, on Experimental Cerebral VasospasmThe Japanese Journal of Pharmacology, 1985
- Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a “two-hemorrhage” canine modelJournal of Neurosurgery, 1983
- Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581Journal of Neurosurgery, 1982
- Cerebral vasospasm: contractile activity of hemoglobin in isolated canine basilar arteriesJournal of Neurosurgery, 1980
- Cerebral arterial smooth muscle contraction by thromboxane A2.Stroke, 1977
- Cerebral arterial spasmJournal of Neurosurgery, 1974